Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. May 14, 2012; 18(18): 2280-2286
Published online May 14, 2012. doi: 10.3748/wjg.v18.i18.2280
Table 1 Serum connective tissue growth factor concentrations in patients with chronic liver diseases (μg/L)
GroupnMedian (95% CI)
Healthy control302.2 (1.6-2.8)
HBV carrier82.2 (1.5-2.9)
Chronic hepatitis B1078.8 (6.0-12.3)
Active liver cirrhosis3910.9 (7.0-14.6)
Table 2 Relationship between fibrosis stage and hepatic or serum connective tissue growth factor content
Fibrosis stagenSerum CCN2(μg/L) median (95% CI)Hepatic CCN2 mRNA(IOD) median (95% CI)
Normal control82.2 (1.5-2.9)6.0 (3.9-8.8)
F1116.8 (5.0-8.9)19.4 (12.3-26.4)
F298.9 (7.1-10.7)25.6 (13.9-34.8)
F3119.4 (7.3-12.0)31.9 (19.7-44.6)
F4810.1 (8.2-12.1)39.6 (25.5-52.8)